Lawmakers probe Novo Nordisk over drug's discontinuation

Senators are demanding to know why Novo Nordisk discontinued Levemir, one of the nation's three long-acting insulins.

In an April 16 letter, New Hampshire Sen. Jeanne Shaheen, Georgia Sen. Raphael Warnock and Massachusetts Sen. Elizabeth Warren asked the Denmark-based drugmaker why Levemir was removed from the U.S. market.